Sun.Aug 11, 2024

article thumbnail

Weekend ICYMI: August 5 to August 9

Drug Topics

In case you missed it, this week we had news about opioid prescribing for patients with chronic pain, a possible link between cannabis and cancer, preparing for the upcoming flu season, and more.

181
181
article thumbnail

Three MDMA therapy papers retracted over data integrity concerns

STAT

The journal Psychopharmacology has retracted three papers about MDMA-assisted psychotherapy — right on the heels of the Food and Drug Administration’s rejection of the closely watched treatment for post-traumatic stress disorder. Many authors on the three studies are affiliated with the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and its commercial spinout Lykos Therapeutics, including founder Rick Doblin, who spearheaded the decades-long efforts to win a

145
145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Expanding Role of Continuous Glucose Monitors in Pregnant Patients

Pharmacy Times

The use of CGMs in pregnancy provides clinicians with essential data in real-time, rather than a snapshot given by traditional finger stick testing.

132
132
article thumbnail

Opinion: Getting to ‘Plan B’ for psychedelic medicine: Lessons from reproductive health

STAT

The Food and Drug Administration’s decision not to approve Lykos Therapeutics’ application for MDMA (a psychedelic drug known on the street as Ecstasy or molly) plus therapy for post-traumatic stress disorder comes as no surprise, given an advisory panel’s “no” vote on the application in June. But if lessons from reproductive health are any signal, I believe there is a future for psychedelics in health care.

FDA 131
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Benazepril Versus Lisinopril

Med Ed 101

Benazepril and lisinopril are both ACE Inhibitors that are commonly used in practice. Lisinopril is the most frequently used ACE inhibitor. In this article, we will compare benazepril versus lisinopril and highlight some of the differences that may help guide the selection of one versus the other. Angiotensin-converting enzyme (ACE) inhibitors are a specific medication […] The post Benazepril Versus Lisinopril appeared first on Med Ed 101.

105
105
article thumbnail

Opinion: Controlling obesity is a noble goal. Controlling mpox is a far more urgent one

STAT

As a global health investor and public health advocate, I understand the benefit of weight loss drugs and the rush to promote Ozempic, Wegovy, and other GLP-1 drugs. What I cannot wrap my head around is how, almost 45 years after the World Health Organization announced that smallpox had been eradicated , the world is once again dealing with smallpox vaccines and treatments, this time aimed at mpox.

Vaccines 125

More Trending

article thumbnail

It’s a Cruel Summer – Two New OPDP Untitled Letters

The FDA Law Blog

By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued two new Untitled Letters this summer after 5 months without any letter activity. The letters are vastly different from one another in subject matter, but together they make a cruel summer of OPDP enforcement against industry. [Editorial note – the Gen X’er included that link first – for the arguably more popular reference, read on.

FDA 59
article thumbnail

How To Convince Physicians To Change Their Antibiotic Prescribing Practices: 5 Lessons From An Antimicrobial Stewardship Pharmacist

IDStewardship

In this article an antimicrobial stewardship pharmacist discusses how to convince physicians to change their antibiotic prescribing practices Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article Posted 12 August 2024 Antimicrobial stewardship is about promoting the safe and rational use of antimicrobial agents. This goal can be achieved in many ways, but a key part of the effort needs to be getting physicians on board with prescribing practices that the antimicrobial stewardship progr